Accelerating accessible
early cancer detection
Powered by OncoSeek®
Multi cancer early detection test
Worldwide each year, 19.3 million people are diagnosed with cancer and the numbers are growing. Nearly 1 in 6 deaths is caused by cancer. The need to expedite diagnosis is vital. Early diagnosis increases chances of survival and reduces the negative impact on quality of life. OncoInv offers OncoSeek®, a multi-cancer early detection blood test.
OncoSeek® is a low cost detection test for cancer
OncoSeek® is a software based early detection test, which analyses the concentrations of a selected number of protein tumor markers with a Machine Learning algorithm. It performs detection of 9 high-mortality cancers, calculating a Probability of Cancer score as wel as a predicted Tissue of Origin. OncoSeek® is scientifically validated, CE-marked and can be easily implemented as it uses existing medical infrastructure.
OncoSeek® can be used anywhere in the world by medical organisations who provide health services to the public.
Learn more about OncoSeek®About Oncolnv
OncoInv is an initiative of Inspire2Live. It’s our mission to ensure that people worldwide have early access to treatment of cancer by means of early detection. OncoInv works together with SeekIn, the developer of OncoSeek®, to reach that mission.
Learn more about OncoInv
News & Updates
Expert roundtable in Madrid discusses integration of multi-cancer detection into clinical practice
February 12th, 2026
OncoInv recently hosted an expert roundtable at Madrid Health Hub, bringing together clinicians, laboratory leaders and researchers to discuss the evolving role of multi-cancer detection (MCD) tests in oncology care...
Read more
Oncology experts discuss the future of multi-cancer detection in Madrid
February 5th, 2026
On February 9, OncoInv will host an exclusive expert meeting at Madrid Health Hub, bringing together leading voices in oncology to discuss the evolving role of multi-cancer early detection (MCD) in clinical practice...
Read more
Jesper Verhey appointed CEO to lead OncoInv's next phase of accelerating impact in early cancer detection
February 3rd, 2026
As of 1 February, Jesper Verhey MSc, has taken on the role of CEO of OncoInv. This step marks the next phase in the company’s development, building on the progress of recent years and placing responsible implementation and real-world evidence generation at the centre of its work...
Read more